Research square · 2026
Novel Plasma Proteins Associated With Alzheimer's Disease Risk in APOE ε4 Carriers and Non-carriers.
СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leng Yuanming, Ding Huitong, Yang Jian, Liu Xue, Lu Alec, Tao Qiushan, Ma Jiantao, Gifford Katherine A, Ang Ting Fang Alvin, Qiu Wei Qiao, Au Rhoda, Doraiswamy P Murali, Liu Chunyu
Аннотация
BACKGROUND: Whether plasma protein associations with Alzheimer's disease (AD) differ by genetic risk remains unclear.
METHODS: We studied 18,212 UK Biobank participants aged ≥ 60 years with Olink Explore 3072 proteomic data, APOE genotypes, and AD polygenic risk scores. Protein-by-genetic risk interactions were screened, followed by genetic risk-stratified association and mediation analyses in Cox models.
RESULTS: During 12.8 years of follow-up, 374 participants developed AD. APOE ε4 carriers had higher AD risk than non-carriers (HR = 7.79 [6.18-9.81]), with the greatest risk among ε4 homozygotes (HR = 17.73 [13.36-23.51]). Stratified analyses identified AD-associated proteins among APOE ε4 non-carriers (n = 85), ε4 carriers (n = 10), and low-, intermediate-, and high-AD-PRS groups (n = 10, 1, and 2, respectively), including 94 newly identified proteins. APOE protein, MENT, and GFAP mediated 34.49%, 25.01%, and 11.47% of the APOE ε4-AD association.
CONCLUSIONS: Genetic risk stratification revealed heterogeneous protein-AD associations and genotype-dependent proteomic pathways.
METHODS: We studied 18,212 UK Biobank participants aged ≥ 60 years with Olink Explore 3072 proteomic data, APOE genotypes, and AD polygenic risk scores. Protein-by-genetic risk interactions were screened, followed by genetic risk-stratified association and mediation analyses in Cox models.
RESULTS: During 12.8 years of follow-up, 374 participants developed AD. APOE ε4 carriers had higher AD risk than non-carriers (HR = 7.79 [6.18-9.81]), with the greatest risk among ε4 homozygotes (HR = 17.73 [13.36-23.51]). Stratified analyses identified AD-associated proteins among APOE ε4 non-carriers (n = 85), ε4 carriers (n = 10), and low-, intermediate-, and high-AD-PRS groups (n = 10, 1, and 2, respectively), including 94 newly identified proteins. APOE protein, MENT, and GFAP mediated 34.49%, 25.01%, and 11.47% of the APOE ε4-AD association.
CONCLUSIONS: Genetic risk stratification revealed heterogeneous protein-AD associations and genotype-dependent proteomic pathways.